MedKoo Cat#: 528527 | Name: NP-252

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NP-252 is a calcium channel antagonist potentially for the treatment of angina pectoris and congestive heart failure. The vasoinhibitory effects of NP-252 were significantly stronger than those of nifedipine in canine cerebral artery. NP-252 (10(-7) and 10(-6) M) dose-dependently attenuated nifedipine-resistant Ca(++)-contraction in the presence of STA2 in both canine cerebral and coronary arteries. The inhibitory effect of combined treatment with NP-252 (10(-6) M) and nitroglycerin (10(-6) M) on nifedipine-resistant Ca(++)-contraction in the cerebral artery was additive. In aorta, only NP-252 reduced total La3+ resistant 45Ca binding. However, the increases in bound 45Ca at La3+ resistant sites and 45Ca unidirectional influx due to KCl were inhibited by both NP-252 and nifedipine.

Chemical Structure

NP-252
NP-252
CAS#132031-81-3

Theoretical Analysis

MedKoo Cat#: 528527

Name: NP-252

CAS#: 132031-81-3

Chemical Formula: C26H35N3O5

Exact Mass: 469.2577

Molecular Weight: 469.58

Elemental Analysis: C, 66.50; H, 7.51; N, 8.95; O, 17.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
NP-252; NP 252; NP252
IUPAC/Chemical Name
octyl 5-(cyclopropylcarbamoyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
InChi Key
IAWVGADTHVEXRD-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H35N3O5/c1-4-5-6-7-8-11-16-34-26(31)23-18(3)27-17(2)22(25(30)28-19-14-15-19)24(23)20-12-9-10-13-21(20)29(32)33/h9-10,12-13,19,24,27H,4-8,11,14-16H2,1-3H3,(H,28,30)
SMILES Code
O=C(C1=C(C)NC(C)=C(C(NC2CC2)=O)C1C3=CC=CC=C3[N+]([O-])=O)OCCCCCCCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 469.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hojo M, Tanaka Y, Katayama O, Teramoto N. Acute antihypertensive effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)-carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitrophen yl) octyl ester on conscious spontaneously hypertensive rats and renal hypertensive rats. Arzneimittelforschung. 1993 Aug;43(8):847-51. PubMed PMID: 8216440. 2: Hojo M, Teramoto N, Hata H, Katayama O, Tatsumi H, Shibata S. Cardiovascular effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitropheny l) octyl ester. Arzneimittelforschung. 1992 May;42(5):621-8. PubMed PMID: 1530674. 3: Shibata S, Satake N, Kodama I, Hester RK, Wang CG, Jino H, Hojo M, Tatsumi H, Gandhi V, Jones DJ. Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol. 1991 Oct 22;203(3):337-44. PubMed PMID: 1773820. 4: Akimoto Y, Kurahashi K, Usui H, Fujiwara M. Vasoinhibitory effect of NP-252, a new dihydropyridine derivative, in canine cerebral artery. Life Sci. 1991;48(2):183-8. PubMed PMID: 1994178.